Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542758 | 0.79 | L3MBTL1 (0.39) | L3MBTL1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL10248252 | 0.79 | MAPK14 (0.36) | L3MBTL1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL15381374 | 0.76 | PARP1 (0.39) | ADORA3ADORA2AADORA1ALDH1A1SMN1; SMN2 | |
| SCHEMBL20033691 | 0.74 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1SMN1; SMN2KCNH2SCN10A | |
| SCHEMBL27203429 | 0.72 | AR (0.32) | AR | |
| SCHEMBL29770337 | 0.72 | AR (0.32) | AR | |
| SCHEMBL22648457 | 0.71 | PARP1 (0.39) | L3MBTL1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL10284439 | 0.71 | GAA (0.42) | ADORA3ADORA2AADORA1SMN1; SMN2AR | |
| SCHEMBL10248304 | 0.69 | SMN1; SMN2 (0.36) | L3MBTL1ADORA3ADORA2AADORA1ALDH1A1 | |
| SCHEMBL10248384 | 0.69 | AR (0.49) | L3MBTL1ALDH1A1SMN1; SMN2KCNH2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-20170313989-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-02 | — | — | US | disclosed |
| US-9670463-B2 | Inhibition and enhancement of reprogramming by chromatin modifying enzymes | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-05-18 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | Epizyme, Inc. | 2017-03-23 | — | — | US | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | Epizyme, Inc. | 2015-12-03 | — | — | US | disclosed |
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | Epizyme, Inc. | 2015-10-08 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | Epizyme, Inc. (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140242046-A1 | INHIBITION AND ENHANCEMENT OF REPROGRAMMING BY CHROMATIN MODIFYING ENZYMES | Childern's Medical Center Corporation (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284422-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | L3MBTL1 151/4885ADORA3 4660/4885ADORA2A 4376/4885 |
| US-20190100552-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | L3MBTL1 151/4885ADORA3 4660/4885ADORA2A 4376/4885 |
| US-20140323421-A1 | Combination Therapy for Treating Cancer | DOT1L, ASH1L, CARM1 | L3MBTL1 474/4885ADORA3 4351/4885ADORA2A 3936/4885 |
| US-20150342979-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | L3MBTL1 412/4885ADORA3 4618/4885ADORA2A 4286/4885 |
| US-20200113923-A1 | DOT1L INHIBITORS FOR USE IN THE TREATMENT OF LEUKEMIA | DOT1L, CARM1, MCL1 | L3MBTL1 412/4885ADORA3 4618/4885ADORA2A 4286/4885 |
| US-20170137455-A1 | INHIBITORS OF PROTEIN METHYLTRANSFERASE DOT1L AND METHODS OF USE THEREOF | DOT1L, PRMT1, CARM1 | L3MBTL1 151/4885ADORA3 4660/4885ADORA2A 4376/4885 |
| US-20170080010-A1 | COMBINATION THERAPY FOR TREATING CANCER | DOT1L, ASH1L, CARM1 | L3MBTL1 474/4885ADORA3 4351/4885ADORA2A 3936/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | L3MBTL1 699/4885ADORA3 446/4885ADORA2A 182/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | L3MBTL1 699/4885ADORA3 446/4885ADORA2A 182/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | L3MBTL1 699/4885ADORA3 446/4885ADORA2A 182/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | L3MBTL1 699/4885ADORA3 446/4885ADORA2A 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.